Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...
Repligen's Q4 Slightly Tops Expectations
In the fourth quarter, Repligen's performance was mixed. Adjusted earnings per share (EPS) surpassed analysts' expectations ...
Repligen price target raised to $170 from $165 at Canaccord
Canaccord raised the firm’s price target on Repligen (RGEN) to $170 from $165 and keeps a Buy rating on the shares. The firm said they reported ...
Repligen outlines 10-14% non-COVID revenue growth for 2025 driven by CDMO and equipment traction
Q4 2024 Management View CEO Olivier Loeillot highlighted that Repligen achieved Q4 2024 revenue of $167.5 million and full-year revenue of $634.4 million, meeting the midpoint of their November ...
Nasdaq2d
Repligen Corporation Reports Fourth Quarter 2024 Revenue of $168 Million and Provides 2025 Financial Guidance
Base revenue (Non-GAAP) excludes COVID-related revenue and acquisition-related revenue contribution in current period for which there was no prior year comparable. For the three- and twelve-month ...
Repligen (RGEN) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Repligen (RGEN – Research Report) today and set a price target of $207.00. The ...
Canaccord上调Repligen目标价至170美元，维持持有评级
周五，Canaccord Genuity分析师调整了对Repligen Corporation（NASDAQ:RGEN）的展望，将12个月目标价从此前的165美元上调至170美元，同时维持对该股的持有评级。此次调整反映了该公司在Canaccord十年期折现现金流（DCF）模型中预计的利润率略有提升。目前，该股交易价格为162.67美元，市值91亿美元，过去一周强劲上涨10.7%。根据 ...